Investment Newsletters

H.C. Wainwright

Seattle Genetics: Recent Macro Weakness Has Created A Buying Opportunity, Says H.C. Wainwright

In a research note released today, H.C.

Ben Mahaney, Editor — August 1, 2014, 3:11 PM EDT

EDAP: Ablatherm Has A 65-70% Chance Of A Positive Panel Vote, Says H.C. Wainwright

In a research report issued Monday, H.C.

Ben Mahaney, Editor — July 28, 2014, 1:50 PM EDT

H.C. Wainwright Reiterates Buy On Agenus Following 2Q14 Results

In a research report issued this morning, H.C.

Ben Mahaney, Editor — July 25, 2014, 9:02 AM EDT

Current Trading Levels Reflect Appropriate Value For VRTX Shares, Says H.C. Wainwright

In a research note released today, H.C.

Ben Mahaney, Editor — July 24, 2014, 1:01 PM EDT

H.C. Wainwright Reiterates Buy On Neptune; Sees 288% Upside For The Stock

H.C.

Ben Mahaney, Editor — July 18, 2014, 9:57 AM EDT

Aeterna Zentaris Shares Are Currently Undervalued And Provide Upside, Says H.C. Wainwright

In a research report released today, H.C.

Ben Mahaney, Editor — July 17, 2014, 3:44 PM EDT

H.C. Wainwright Reiterates Buy On Celsion Following Meeting With Management

In a research report issued today, H.C.

Ben Mahaney, Editor — July 16, 2014, 3:28 PM EDT

H.C. Wainwright Initiates Buy On IntelGenx Technologies; Sees %186 Upside

In a research report released this morning, H.C.

Ben Mahaney, Editor — June 30, 2014, 8:23 AM EDT

Agenus Represents An Undervalued Player In The Immuno-Oncology Space, Says H.C. Wainwright

In a research note issued this morning, H.C.

Ben Mahaney, Editor — June 27, 2014, 8:40 AM EDT

Quick Thoughts: EDAP Represents An Undervalued Stock With Significant Upside

In a research note issued last week, H.C.

Ben Mahaney, Editor — June 27, 2014, 8:09 AM EDT

« 1 … 18 19 20 21 »